Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Down 19.5% in February

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 9,900 shares, a decline of 19.5% from the February 13th total of 12,300 shares. Based on an average trading volume of 5,900 shares, the days-to-cover ratio is currently 1.7 days.

Clinuvel Pharmaceuticals Stock Performance

OTCMKTS CLVLY opened at $7.41 on Tuesday. Clinuvel Pharmaceuticals has a 52 week low of $6.80 and a 52 week high of $11.40. The business has a 50 day moving average price of $7.40 and a 200-day moving average price of $8.43.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).